Versions Compared

Old Version 80

changes.mady.by.user Unknown User (amgarcia@mit.edu)

Saved on

compared with

New Version 81

changes.mady.by.user Unknown User (clrichar@mit.edu)

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
TASKWhoDunnitObserved
Split cellsAG, CR, GB, JA, LA, SSAW
Seed platesAG, CR, GB, LA, SSAW
TransfectionAG, GB, LAAC, SS
FACS PrepAG, LACR
Imaging (FloCyto)BTAG, AW, CR, JX, LA

 

Practice Transfections:

Toggle Cloak
CONTROLS

Cloak
  1. +ve: single color transfection (eYFP, eBFP or mKate, as appropriate)
  2. +ve/+ve: tri-color control (eYFP, eBFP and mKate co-transfected: allows for comparison of color/intensity when imaging)
  3. -ve: perform protocol, excluding DNA, or with dummy DNA
  4. -ve/-ve: no actions performed on cells

Toggle Cloak
PRACTICE #1: Fluorescent protein under constitutive promoter

Cloak
11 complete 6/23: Seed cells 12 complete 6/24: Transfect hEF1a:eYFP (472 ng/uL) into HEK cells 13 complete 6/26 (4.30pm): Flow Cytometer
  • Determine optimal Lipofectamine LTX volume (24 well)
  • Determine transfection efficiency (quantitatively)

RESULT: Decent transfection efficiency (~60%). Move on to Practice #2.

Toggle Cloak
PRACTICE #2: Co-transfection (2 fluorescent proteins under constitutive promoter)

Cloak

ATTEMPT #1

36 complete 7/3: Seed cells 23 complete 7/4: Transfect hEF1a:eYFP (472 ng/uL) and hEF1a:tagBFP (1176 ng/uL) into HEK cells 24 complete 7/6 (1pm): Flow Cytometer

 

  • DNA Dilution: 10uL hEF1a:eYFP; 5uL hEF1a:tagBFP
  • (Y+B)x: add 1:1 (25uL hEF1a:eYFP/tagBFP-lipid complex)
Y1
  • hEF1a:eYFP
(Y+B)1
  • hEF1a:eYFP
  • hEF1a:tagBFP
 ////// ////// ////// -ve control
  • dummy DNA
  • with Lipofectamine
Y2
  • hEF1a:eYFP
(Y+B)2
  • hEF1a:eYFP
  • hEF1a:tagBFP
 ////// ////// ////// -ve control
  • dummy DNA
  • with Lipofectamine
B1
  • hEF1a:tagBFP
(Y+B)3
  • hEF1a:eYFP
  • hEF1a:tagBFP
 ////// ////// ////// -ve/-ve control
  • no DNA
  • no Lipofectamine
B2
  • hEF1a:tagBFP
(Y+B)4
  • hEF1a:eYFP
  • hEF1a:tagBFP
 ////// ////// ////// -ve/-ve control
  • no DNA
  • no Lipofectamine

RESULT: Extremely low transfection efficiency (<10%). Repeat to improve co-transfection results.

 

ATTEMPT #2

22 complete 7/9: Seed cells 37 complete 7/10: Transfect hEF1a:mKate (621 ng/uL) and hEF1a:eBFP (405 ng/uL) into HEK cells 38 complete 7/12 (1:30pm): Flow Cytometer

 

  • DNA Dilution: 8.1uL (10 uL) hEF1a:mKate; 12.3uL (15 uL) hEF1a:eBFP
  • (R+B)x: add 1:1 (25uL hEF1a:mKate/eBFP-lipid complex)
R1
  • hEF1a:mKate
(R+B)1
  • hEF1a:mKate
  • hEF1a:eBFP
//////////////////-ve control
  • dummy DNA
  • with Lipofectamine
R2
  • hEF1a:mKate
(R+B)2
  • hEF1a:mKate
  • hEF1a:eBFP
//////////////////-ve control
  • dummy DNA
  • with Lipofectamine
B1
  • hEF1a:eBFP
(R+B)3
  • hEF1a:mKate
  • hEF1a:eBFP
//////////////////-ve/-ve control
  • no DNA
  • no Lipofectamine
B2
  • hEF1a:eBFP
(R+B)4
  • hEF1a:mKate
  • hEF1a:eBFP
//////////////////-ve/-ve control
  • no DNA
  • no Lipofectamine

RESULT: Efficiency ~20%

 

Toggle Cloak
PRACTICE #3: Fluorescent protein under inducible promoter (DOX ladder)

Cloak
14 complete 7/10: Seed cells 15 complete 7/11: Transfect TRE:mKate (431 ng/uL), hEF1a:rtTA (169 ng/uL) and hEF1a:eYFP (1045 ng/uL - transfection marker) into HEK cells 16 complete 7/12: Add DOX 18 complete 7/13 (1:30pm): Flow Cytometer

 

  • DNA Dilution: 4.8uL hEF1a:eYFP; 29.6uL hEF1a:rtTA; 11.6uL TRE:mKate
  • Conc. of DOX: 1mg/uL
  • (D=x): add 2:1:2
    1. 20uL hEF1a:eYFP-lipid complex
    2. 10uL hEF1a:rtTA-lipid complex
    3. 20uL TRE:mKate-lipid complex

 

+ve control
  • hEF1a:eYFP
+ve control
  • hEF1a:eYFP
-ve control
  • dummy DNA
  • with Lipofectamine
-ve control
  • dummy DNA
  • with Lipofectamine
-ve/-ve control
  • no DNA
  • no Lipofectamine
-ve/-ve control
  • no DNA
  • no Lipofectamine
////////////////////////////////////
(D=0)1
  • no DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
(D=0)2
  • no DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=1
  • 1mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=2(*3)
  • 2mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=3(*5)
  • 3mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=4(*10)
  • 4mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=5(*2)
  • 5mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=6(*4)
  • 6mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=7(*6)
  • 7mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=8(*7)
  • 8mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=9(*8)
  • 9mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate
D=10(*9)
  • 10mg DOX
  • hEF1a:eYFP
  • hEF1a:rtTA
  • TRE:mKate

RESULTS: Efficiency >50%


SUBGROUP-SPECIFIC PRACTICE EXPERIMENTS

Inducible and Constitutive Cascades